镇江德瑞药物有限公司为南京海辰药业股份有限公司的全资子公司，注册资金1.22亿。其坐落在镇江新区国际化学工业园。

镇江德瑞药物有限公司作为母公司原料药生产基地，旨在扩大原料药的生产规模，更好地开拓海外市场，以实现南京海辰药业股份有限公司原料药--制剂产业链一体化发展。同时，镇江德瑞药物有限公司将以新建原料药基地为契机，加快推进原料药品种美国FDA认证、欧盟COS认证等工作，从而实现原料药产品的海外销售，为公司发展提供新的经济增长点。

Zhenjiang Dery Pharmaceutical Co., Ltd is a wholly-owned subsidiary of Nanjing Hicin Pharmaceutical Co., Ltd, with a registered capital of 22 million and a total investment of 108 million. It is located in International Chemical Industrial Park of Zhenjiang New District.

As the API production base of its parent company, Zhenjiang Dery Pharmaceutical Co., Ltd. is aimed at expanding the production capacity of APIs and intermediates, and opening up overseas markets, in order to achieve preparation industry chain integration. At the same time, Zhenjiang Dery Pharmaceutical Co., Ltd. will take the new API base as an opportunity to speed up US FDA certification and EU COS certification of its API products, so as to achieve the overseas sales of API products.